Iterum Therapeutics Announces Expiration and Results of Rights Offering
06 août 2024 17h30 HE
|
Iterum Therapeutics PLC
DUBLIN and CHICAGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and...
Iterum Therapeutics Broadens Patent Estate for Oral Sulopenem
02 août 2024 08h00 HE
|
Iterum Therapeutics PLC
DUBLIN and CHICAGO, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next generation oral and IV...
Iterum Therapeutics Commences Rights Offering
22 juil. 2024 07h30 HE
|
Iterum Therapeutics PLC
DUBLIN and CHICAGO, July 22, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and...
Iterum Therapeutics Announces FDA Advisory Committee Meeting to discuss NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections
21 juin 2024 08h00 HE
|
Iterum Therapeutics PLC
DUBLIN, Ireland and CHICAGO, June 21, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics to Present Data at ASM Microbe 2024
05 juin 2024 08h00 HE
|
Iterum Therapeutics PLC
DUBLIN and CHICAGO, June 05, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV...
Iterum Therapeutics Receives FDA Acceptance of Resubmission of NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections
31 mai 2024 08h00 HE
|
Iterum Therapeutics PLC
DUBLIN and CHICAGO, May 31, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV...
Iterum Therapeutics Reports First Quarter 2024 Financial Results
13 mai 2024 07h00 HE
|
Iterum Therapeutics PLC
--NDA Resubmitted; FDA Action Expected in Early Q4 24-- --Cash Runway into 2025, including through Potential FDA Approval-- --Company to Host Conference Call Today at 8:30 a.m. EDT-- ...
Iterum Therapeutics to Report First Quarter 2024 Financial Results on May 13, 2024
06 mai 2024 08h00 HE
|
Iterum Therapeutics PLC
DUBLIN, Ireland and CHICAGO, May 06, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral...
Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem
29 avr. 2024 08h00 HE
|
Iterum Therapeutics PLC
--First Oral Penem in the U.S. and Second New Oral Treatment for uUTIs in Over 25 Years, if approved-- --Potential Approval Early Q4 2024-- DUBLIN, Ireland and CHICAGO, April 29, 2024 (GLOBE...
Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
28 mars 2024 07h00 HE
|
Iterum Therapeutics PLC
--Resubmission of NDA On Track for Early Q2 24— --Cash Runway into 2025, including through Potential FDA Approval in Early Q4 24-- --Company to host conference call today at 8:30amET-- DUBLIN,...